A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
← catalyst calendarNCT05307705 · readout ≤ 134 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
260estimated
Sites
50
Countries
Australia, Belgium, Canada +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-11 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: LOXO-783 — also filed as LY3849524
- Drug: Fulvestrant
- Drug: Imlunestrant — also filed as LY3484356
- Drug: Abemaciclib — also filed as LY2835219
- Drug: Anastrozole, Exemestane, or Letrozole
- Drug: Paclitaxel
Primary outcomes
what the primary-completion date above is the date OFPhase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)
measured During the first 28-day cycle of LOXO-783 treatment
Phase 1 a: To determine the MTD/RP2D of LOXO-783: Number of patients with DLT-equivalent toxicities
measured During the first 28-day cycle of LOXO-783 treatment
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed